HC Wainwright restated their buy rating on shares of Verastem, Inc. (NASDAQ:VSTM) in a research report sent to investors on Wednesday morning. They currently have a $10.00 price target on the biopharmaceutical company’s stock.

Several other research firms also recently commented on VSTM. Oppenheimer Holdings, Inc. reissued a buy rating and issued a $6.00 target price on shares of Verastem in a research report on Thursday, October 12th. Cantor Fitzgerald set a $17.00 target price on shares of Verastem and gave the stock a buy rating in a research report on Tuesday, October 17th. Zacks Investment Research raised shares of Verastem from a hold rating to a buy rating and set a $3.75 target price for the company in a research report on Thursday, July 13th. ValuEngine downgraded shares of Verastem from a hold rating to a sell rating in a research report on Friday, September 1st. Finally, Cann reissued a buy rating and issued a $6.00 target price on shares of Verastem in a research report on Tuesday, July 25th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and five have assigned a buy rating to the company. Verastem presently has an average rating of Buy and a consensus target price of $7.18.

Shares of Verastem (VSTM) opened at $3.47 on Wednesday. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.12 and a quick ratio of 5.40. Verastem has a 1 year low of $1.05 and a 1 year high of $5.71.

Verastem (NASDAQ:VSTM) last posted its earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.61) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.32) by ($0.29). equities research analysts forecast that Verastem will post -1.67 EPS for the current fiscal year.

TRADEMARK VIOLATION NOTICE: “Verastem, Inc. (VSTM) Stock Rating Reaffirmed by HC Wainwright” was first posted by Watch List News and is owned by of Watch List News. If you are reading this story on another site, it was copied illegally and reposted in violation of U.S. & international trademark and copyright law. The original version of this story can be viewed at https://www.watchlistnews.com/verastem-inc-vstm-stock-rating-reaffirmed-by-hc-wainwright/1697823.html.

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Renaissance Technologies LLC boosted its holdings in shares of Verastem by 20.0% during the 1st quarter. Renaissance Technologies LLC now owns 1,226,600 shares of the biopharmaceutical company’s stock worth $2,539,000 after buying an additional 204,400 shares during the period. Vanguard Group Inc. boosted its holdings in shares of Verastem by 10.3% during the 2nd quarter. Vanguard Group Inc. now owns 1,143,642 shares of the biopharmaceutical company’s stock worth $2,493,000 after buying an additional 107,029 shares during the period. Artal Group S.A. boosted its holdings in shares of Verastem by 50.0% during the 3rd quarter. Artal Group S.A. now owns 750,000 shares of the biopharmaceutical company’s stock worth $3,525,000 after buying an additional 250,000 shares during the period. EAM Investors LLC bought a new stake in shares of Verastem during the 3rd quarter worth $2,092,000. Finally, Howland Capital Management LLC boosted its holdings in shares of Verastem by 16.5% during the 2nd quarter. Howland Capital Management LLC now owns 294,007 shares of the biopharmaceutical company’s stock worth $641,000 after buying an additional 41,616 shares during the period. 24.25% of the stock is owned by institutional investors and hedge funds.

About Verastem

Verastem, Inc is a biopharmaceutical company. The Company is focused on discovering and developing drugs to improve outcomes for patients with cancer. The Company operates in the segment of developing drugs for the treatment of cancer. The Company’s advanced product candidates are VS 6063, VS 4718 and VS 5584.

Analyst Recommendations for Verastem (NASDAQ:VSTM)

Receive News & Ratings for Verastem Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Verastem Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.